Cat. No.: HY-154487

Glycerol dioleate

Customer Review

Based on 1 Customer Validation

Glycerol dioleate is a lipid capable of forming Lyotropic Liquid Crystal (LLC). When formulated with phosphatidylcholine and exposed to aqueous media, glycerol dioleate constructs an inverted hexagonal (H_II) phase structure with sustained-release properties. The in-situ forming gel prepared by optimizing glycerol dioleate with phosphatidylcholine and N-methyl-2-pyrrolidone enables stable release of Risperidone (HY-11018) for up to 60 days in vitro and in vivo. Glycerol dioleate causes minimal side effects in rabbits, making it an ideal carrier component for the development of antischizophrenia agents.Note: Lyotropic liquid crystals (Lyotropic Liquid Crystal, LLC) are ordered fluid phases self-assembled by amphipathic molecules (e.g., lipids, surfactants) in solvents (usually water) at specific concentrations.

For research use only. We do not sell to patients.

Purity: 98.0%
CAS No.: 25637-84-7
Formula: C₃₉H₇₂O₅
Molecular Weight:621.00

Storage:

-20°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Glycerol dioleate Chemical Structure

CAS No.: 25637-84-7

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
- Parmacokinetics
- In Vivo
Chemical Information
Solvent & Solubility
- In Vitro
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

Glycerol dioleate is a lipid capable of forming Lyotropic Liquid Crystal (LLC). When formulated with phosphatidylcholine and exposed to aqueous media, glycerol dioleate constructs an inverted hexagonal (H_II) phase structure with sustained-release properties. The in-situ forming gel prepared by optimizing glycerol dioleate with phosphatidylcholine and N-methyl-2-pyrrolidone enables stable release of Risperidone (HY-11018) for up to 60 days in vitro and in vivo. Glycerol dioleate causes minimal side effects in rabbits, making it an ideal carrier component for the development of antischizophrenia agents^[1].Note: Lyotropic liquid crystals (Lyotropic Liquid Crystal, LLC) are ordered fluid phases self-assembled by amphipathic molecules (e.g., lipids, surfactants) in solvents (usually water) at specific concentrations^[1].

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	>10 μM Compound: 7	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 28445049]
HepG2	IC₅₀	>10 μM Compound: 7	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 28445049]
MDA-MB-231	IC₅₀	>10 μM Compound: 7	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 28445049]
Neutrophil	IC₅₀	>10 μM Compound: 7	Anti-inflammatory activity in human neutrophils assessed as inhibition of fMLF/CB-induced elastase release by measuring degranulation of azurophilic granules using MeOSuc-Ala-Ala-ProVal-p-nitroanilide as substrate preincubated for 5 mins followed by CB/fM Anti-inflammatory activity in human neutrophils assessed as inhibition of fMLF/CB-induced elastase release by measuring degranulation of azurophilic granules using MeOSuc-Ala-Ala-ProVal-p-nitroanilide as substrate preincubated for 5 mins followed by CB/fM	[PMID: 28445049]
Neutrophil	IC₅₀	>10 μM Compound: 7	Anti-inflammatory activity in human neutrophils assessed as inhibition of fMLF/CB-induced superoxide anion generation preincubated for 5 mins followed by CB stimulation for 3 mins and subsequent fMLF stimulation for 10 mins by spectrophotometric method Anti-inflammatory activity in human neutrophils assessed as inhibition of fMLF/CB-induced superoxide anion generation preincubated for 5 mins followed by CB stimulation for 3 mins and subsequent fMLF stimulation for 10 mins by spectrophotometric method	[PMID: 28445049]

In Vitro

Glycerol dioleate-based LLC formulations (PC:GDO ratio of 2.1:1, containing 30% NMP (w/w); stable for up to 60 days) achieve uniform, sustained release of risperidone for up to 60 days in vitro^[1].
Glycerol dioleate-based LLC formulations degrade and release free oleic acid in vitro, with a cumulative release of 16.68 mg in 75 mL of culture medium over 60 days^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Parmacokinetics

Species	Dose	Route	T_max	C_max	T_1/2	MRT	AUC_0-t
Rabbit^[1]	500 mg mg/L	s.c.	366 ± 4.18 h	47.31 ± 3.12 ng/mL	389.22 ± 7.22 h	850.51 ± 10.48 h	57523.90 ± 49.76 ng·h/mL

In Vivo

A glycerol dioleate-based LLC formulation (500 mg; s.c.; single injection) achieves uniform and sustained maintenance of serum risperidone concentrations in rabbits for up to 60 days, with an elimination half-life of 389.22 h, and causes no histopathological damage to major organs^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

New Zealand rabbit (male, 2 ± 0.1 kg)^[1]
Dosage:

500 mg of glycerol dioleate-based LLC formulation (containing 25 mg risperidone)
Administration:

s.c.; single injection
Result:

Formed an opaque, self-assembling gel-like mesophase immediately at the subcutaneous injection site. Reached a maximum risperidone serum concentration (Cmax) of 47.31 ± 3.12 ng/mL at 366 ± 4.18 hours (Tmax). Achieved an elimination half-life (t1/2) of 389.22 ± 7.22 hours, a mean residence time (MRT) of 850.51 ± 10.48 hours, and an area under the serum concentration-time curve (AUC0-t) of 57523.90 ± 49.76 ng·h/mL. Maintained uniform, continuous risperidone serum concentrations for 60 days. Caused subcutaneous adipose tissue necrosis with mononuclear inflammatory cell infiltration at the injection site, but showed no abnormalities, necrosis, hemorrhage, or inflammatory cell infiltration in heart, kidney, or liver tissues.

Chemical Information

CAS No. 25637-84-7
Appearance Oil
Molecular Weight 621.00
Formula C₃₉H₇₂O₅
Color White to off-white
SMILES

CCCCCCCC/C=C\CCCCCCCC(OC(COC(CCCCCCC/C=C\CCCCCCCC)=O)CO)=O.CCCCCCCC/C=C\CCCCCCCC(OCC(COC(CCCCCCC/C=C\CCCCCCCC)=O)O)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

-20°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (161.03 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.6103 mL

8.0515 mL

16.1031 mL

5 mM

0.3221 mL

1.6103 mL

3.2206 mL

10 mM

0.1610 mL

0.8052 mL

1.6103 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (268 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Shiadeh S N R, et al. A sustain-release lipid-liquid crystal containing risperidone based on glycerol monooleate, glycerol dioleate, and glycerol trioleate: In-vitro evaluation and pharmacokinetics in rabbits[J]. Journal of Drug Delivery Science and Technology, 2022, 70: 103257.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.6103 mL	8.0515 mL	16.1031 mL	40.2576 mL
	5 mM	0.3221 mL	1.6103 mL	3.2206 mL	8.0515 mL
	10 mM	0.1610 mL	0.8052 mL	1.6103 mL	4.0258 mL
	15 mM	0.1074 mL	0.5368 mL	1.0735 mL	2.6838 mL
	20 mM	0.0805 mL	0.4026 mL	0.8052 mL	2.0129 mL
	25 mM	0.0644 mL	0.3221 mL	0.6441 mL	1.6103 mL
	30 mM	0.0537 mL	0.2684 mL	0.5368 mL	1.3419 mL
	40 mM	0.0403 mL	0.2013 mL	0.4026 mL	1.0064 mL
	50 mM	0.0322 mL	0.1610 mL	0.3221 mL	0.8052 mL
	60 mM	0.0268 mL	0.1342 mL	0.2684 mL	0.6710 mL
	80 mM	0.0201 mL	0.1006 mL	0.2013 mL	0.5032 mL
	100 mM	0.0161 mL	0.0805 mL	0.1610 mL	0.4026 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Glycerol dioleate

Biological Activity

Chemical Information

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Glycerol dioleate Related Classifications

HY-154487 Related Classifications